On March 22, 2021, Noile-Immune Biotech Inc. closed the transaction. The company has amended the terms and received approximately ¥2,380,000,000 in the transaction. The transaction included participation from new investors Binex Holdings Co., Ltd., Shibuya Corporation (TSE:6340), The Dai-ichi Life Insurance Company, Limited, Healthcare Innovation Investment Limited Partnership, and KD Bio Investment Fund 4, and existing investor BiGEN Co., Ltd. The company has received ¥1,380,001,197 in its second tranche.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,300 KRW | -4.58% | -18.97% | +37.43% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+37.43% | 290M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- A053030 Stock
- News BINEX Co., Ltd.
- Noile-Immune Biotech Inc. announced that it has received ¥2.38 billion in funding from BINEX Co., Ltd., Binex Holdings Co., Ltd., Shibuya Corporation, The Dai-ichi Life Insurance Company, Limited, BiGEN Co., Ltd.